RGC vs. RMD: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at RGC and RMD, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | RGC | RMD |
|---|---|---|
| Company Name | Regencell Bioscience Holdings Limited | ResMed Inc. |
| Country | Hong Kong | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Pharmaceuticals | Health Care Equipment & Supplies |
| Market Capitalization | 6.10 billion USD | 42.32 billion USD |
| Exchange | NasdaqCM | NYSE |
| Listing Date | July 16, 2021 | June 2, 1995 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of RGC and RMD by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | RGC | RMD |
|---|---|---|
| 5-Day Price Return | -7.08% | 1.52% |
| 13-Week Price Return | 20.60% | 14.10% |
| 26-Week Price Return | 12,370.00% | 20.70% |
| 52-Week Price Return | 5,568.18% | 24.97% |
| Month-to-Date Return | -5.53% | 6.30% |
| Year-to-Date Return | 9,492.31% | 26.40% |
| 10-Day Avg. Volume | 0.26M | 0.92M |
| 3-Month Avg. Volume | 2.29M | 0.99M |
| 3-Month Volatility | 644.75% | 18.28% |
| Beta | 2.37 | 0.84 |
Profitability
Return on Equity (TTM)
RGC
-54.75%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
RGC has a negative Return on Equity of -54.75%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
RMD
25.51%
Health Care Equipment & Supplies Industry
- Max
- 34.53%
- Q3
- 19.38%
- Median
- 9.52%
- Q1
- 4.86%
- Min
- -7.58%
In the upper quartile for the Health Care Equipment & Supplies industry, RMD’s Return on Equity of 25.51% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
RGC
--
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
Net Profit Margin data for RGC is currently unavailable.
RMD
27.22%
Health Care Equipment & Supplies Industry
- Max
- 23.34%
- Q3
- 13.06%
- Median
- 9.53%
- Q1
- 5.96%
- Min
- -3.87%
RMD’s Net Profit Margin of 27.22% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.
Operating Profit Margin (TTM)
RGC
--
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
Operating Profit Margin data for RGC is currently unavailable.
RMD
32.75%
Health Care Equipment & Supplies Industry
- Max
- 29.44%
- Q3
- 17.80%
- Median
- 13.95%
- Q1
- 8.73%
- Min
- -3.56%
RMD’s Operating Profit Margin of 32.75% is exceptionally high, placing it well above the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.
Profitability at a Glance
| Symbol | RGC | RMD |
|---|---|---|
| Return on Equity (TTM) | -54.75% | 25.51% |
| Return on Assets (TTM) | -51.38% | 18.61% |
| Net Profit Margin (TTM) | -- | 27.22% |
| Operating Profit Margin (TTM) | -- | 32.75% |
| Gross Profit Margin (TTM) | -- | 59.33% |
Financial Strength
Current Ratio (MRQ)
RGC
42.68
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
RGC’s Current Ratio of 42.68 is exceptionally high, placing it well outside the typical range for the Pharmaceuticals industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.
RMD
3.44
Health Care Equipment & Supplies Industry
- Max
- 4.90
- Q3
- 3.05
- Median
- 2.14
- Q1
- 1.49
- Min
- 0.86
RMD’s Current Ratio of 3.44 is in the upper quartile for the Health Care Equipment & Supplies industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
Debt-to-Equity Ratio (MRQ)
RGC
0.00
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
Falling into the lower quartile for the Pharmaceuticals industry, RGC’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
RMD
0.11
Health Care Equipment & Supplies Industry
- Max
- 1.49
- Q3
- 0.71
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
Falling into the lower quartile for the Health Care Equipment & Supplies industry, RMD’s Debt-to-Equity Ratio of 0.11 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio (TTM)
RGC
--
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
Interest Coverage Ratio data for RGC is currently unavailable.
RMD
661.20
Health Care Equipment & Supplies Industry
- Max
- 58.29
- Q3
- 25.56
- Median
- 9.06
- Q1
- 3.60
- Min
- -28.92
With an Interest Coverage Ratio of 661.20, RMD demonstrates a superior capacity to service its debt, placing it well above the typical range for the Health Care Equipment & Supplies industry. This stems from either robust earnings or a conservative debt load.
Financial Strength at a Glance
| Symbol | RGC | RMD |
|---|---|---|
| Current Ratio (MRQ) | 42.68 | 3.44 |
| Quick Ratio (MRQ) | 41.89 | 2.16 |
| Debt-to-Equity Ratio (MRQ) | 0.00 | 0.11 |
| Interest Coverage Ratio (TTM) | -- | 661.20 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
RGC
0.00%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
RGC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
RMD
0.74%
Health Care Equipment & Supplies Industry
- Max
- 4.05%
- Q3
- 1.76%
- Median
- 0.71%
- Q1
- 0.00%
- Min
- 0.00%
RMD’s Dividend Yield of 0.74% is consistent with its peers in the Health Care Equipment & Supplies industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
RGC
0.00%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
RGC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
RMD
22.19%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 72.47%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
RMD’s Dividend Payout Ratio of 22.19% is within the typical range for the Health Care Equipment & Supplies industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | RGC | RMD |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.74% |
| Dividend Payout Ratio (TTM) | 0.00% | 22.19% |
Valuation
Price-to-Earnings Ratio (TTM)
RGC
--
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for RGC is currently unavailable.
RMD
30.13
Health Care Equipment & Supplies Industry
- Max
- 73.48
- Q3
- 51.69
- Median
- 34.31
- Q1
- 25.74
- Min
- 11.47
RMD’s P/E Ratio of 30.13 is within the middle range for the Health Care Equipment & Supplies industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
RGC
--
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
P/S Ratio data for RGC is currently unavailable.
RMD
8.20
Health Care Equipment & Supplies Industry
- Max
- 9.53
- Q3
- 5.26
- Median
- 3.39
- Q1
- 2.13
- Min
- 0.00
RMD’s P/S Ratio of 8.20 is in the upper echelon for the Health Care Equipment & Supplies industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
RGC
9.57
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
RGC’s P/B Ratio of 9.57 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
RMD
6.34
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 5.98
- Median
- 3.48
- Q1
- 2.43
- Min
- 0.69
RMD’s P/B Ratio of 6.34 is in the upper tier for the Health Care Equipment & Supplies industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | RGC | RMD |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 30.13 |
| Price-to-Sales Ratio (TTM) | -- | 8.20 |
| Price-to-Book Ratio (MRQ) | 9.57 | 6.34 |
| Price-to-Free Cash Flow Ratio (TTM) | -- | 25.57 |